Glioblastoma Multiforme Treatment Market Report Scope & Overview:

To Get More Information on Glioblastoma Multiforme Treatment Market - Request Sample Report

Glioblastoma Multiforme Treatment Market was valued at USD 2.76 billion in 2023 and is expected to reach USD 5.98 billion by 2032, growing at a CAGR of 9% over the forecast period 2024-2032.

The Glioblastoma Multiforme (GBM) Treatment Market Report provides key statistical insights and trends shaping the industry. The incidence and prevalence rates are provided, emphasizing its global burden. The report studies treatment adoption trends and compares the use of standard therapies to those for new treatments, such as immunotherapy. Examining prescription trends by region uncovers differences in drug use and drug volume analysis follows the patterns of manufacture and consumption. It also looks at health spending, dissecting government, insurance, and out-of-pocket spending. The report examines trends in clinical trial and R&D investments and highlights progress on new therapies and precision medicine. These insights help stakeholders understand market dynamics, key drivers, and future opportunities in GBM treatment. The Increasing prevalence of Glioblastoma Multiforme (GBM), advancements in treatment options, and the rising number of research and development activities are the factors driving the Glioblastoma Multiforme (GBM) Treatment market.

Market Dynamics

Drivers

• Increasing incidence of glioblastoma, particularly among aging populations, is driving the demand for effective treatments.

The increasing prevalence of glioblastoma multiforme (GBM), especially in the elderly population, represents the key factor boosting the demand for effective treatment. GBM is one of the most aggressive brain tumors and accounts for a significant number of the brain tumor type stats. Affecting about 40,000 new brain tumor patients diagnosed per year in India, it accounts for nearly 24000 deaths per year. Such increases in life expectancy across the globe have led to an increase in the elderly population, also at risk of all types of cancers, including GBM. This demographic trend contributes to the rising number of GBM cases. For instance, the total cancer incidence rate in India is expected to increase from 1.4 million new cases per year to 2 million by the year 2040, indicating the increasing cancer burden.

The increasing incidence of GBM has spurred research into more effective therapies. Recent work has highlighted existing drugs that may have utility against GBM. For instance, the antidepressant vortioxetine has been found in preclinical studies to shrink GBM tumors. This finding underscores the possibility of evaluating existing drugs in new settings where there is a tremendous need, such as GBM. The increasing prevalence of GBM, especially with the aging population, is an important contributor to the need for better therapies. It highlights the importance of continuing to research and develop ways to improve patient outcomes with this difficult disease.

Restraints:

• High costs and limited efficacy of current therapies pose significant challenges to patient access and treatment outcomes.

The high costs and low efficacy of existing therapies significantly limit the treatment landscape for glioblastoma multiforme (GBM). In the United States, patients with low-grade glioma have out-of-pocket costs between $811 and $1,164 within 90 days of surgery, and the addition of chemotherapy adds another $274 to $301 to these out-of-pocket costs. Many patients will avoid seeking medical care or at least push delays in doing so for financial reasons, with more than 10% reporting such actions directly to surveyors due to costs. Moreover, nearly 25% of patients accumulate brain tumor-related debts, over 50% require unpaid time off work, and 46% either retire or cease working, highlighting substantial indirect costs and productivity losses. Economically, this burden is also substantial, though variable internationally. As an example, the average expenses for GBM are $5,500 in India compared to $110,000 in the United States. Cost estimates from other countries are more in the 200k to 300k range, highlighting the global financial burdens associated with GBM treatment.

The prognosis for GBM patients is poor, even with aggressive treatment approaches. A new combination of olaptesed pegol with bevacizumab and radiotherapy showed a median overall survival of 19.9 months in a recent study compared to 10.5 months with standard care. Even with these improvements, however, the prognosis remains wretched and highlights the urgent need for more effective therapies. Such insufficient efficacy, coupled with exorbitant treatment expenses, poses significant burdens on both patients and the healthcare system and underscores the urgent need for new, more effective, and cost-effective therapeutic approaches for GBM management.

Opportunities:

• Development of personalized medicine approaches and biomarker-driven therapies offers potential for more effective, tailored treatments.

With the rapid advancement of personalized medicine and biomarker-driven therapies, targeting for oncogenic pathways in highly aggressive brain tumor glioblastoma multiforme (GBM) with scarce effective therapies is an attractive opportunity for improvement of the disease treatment outcome. In recent years, specific genetic alterations in GBM tumors have been characterized, proposing several new potential targets for targeted therapy. For example, among 1,035 samples of GBM, mutations were found in 39 of 48 genes tested, while 19% expressed the variant EGFRvIII, and 43% had MGMT promoter methylation. Based on these results, a Phase III clinical trial has been initiated to determine the effect of enzastaurin (DB102), in combination with temozolomide and radiation therapy, in patients with newly diagnosed GBM. The trial uses Denovo Genomic Marker 1 (DGM1) to select patients who may best respond to this therapy, demonstrating a trend towards biomarker-directed approaches.

In a recent influential case, Professor Richard Scolyer, a preeminent melanoma pathologist who was diagnosed with grade-4 IDH-wildtype glioblastoma in late 2023, received a unique treatment modality consisting of immunotherapy, surgery, chemotherapy, and radiotherapy. As a result, the personalized approach yielded promising early results, with no cancer recurrence observed in follow-up evaluations. Such developments emphasize the need for personalized medicine in treating GBM, demonstrating the clinical utility of genetic profiling and biomarker identification to optimize therapy. Such strategies aim to enhance patient outcomes by targeting the unique molecular characteristics of each tumor, paving the way for more precise and effective interventions.

Challenges:

• Reimbursement issues and stringent regulatory compliances associated with glioblastoma multiforme treatment hinder market growth.

Challenges arise from reimbursement issues and stringent regulatory compliances in the treatment landscape of glioblastoma multiforme (GBM), affecting both patients and healthcare providers. Patients receiving treatment for GBM frequently face high levels of out-of-pocket (OOP) spending despite insurance coverage. One study of 43 patients reported a median monthly out-of-pocket (OOP) cost of $1342, ranging from $333 to $17,267. Medication copayments (median, $710), transportation ($327), and hospital bill copayments ($403) accounted for the largest contributors to these expenses. Such financial burdens can result in avoided or delayed medical care; more than 10 percent of patients with brain tumors reported such behaviour, citing cost. Stringent regulations obstruct the development and approval of novel GBM therapies. GBM's complexity, combined with the specialized environment of the brain, requires extensive safety and efficacy testing, which extends the approval timeline further. This complexity discourages investment in innovative treatments and limits therapy innovations for patients. Consequently, the combination of high treatment costs and stringent regulatory hurdles poses significant challenges to improving outcomes in the GBM treatment market.

Segment Analysis

By Drug Class

The other segment dominated the Glioblastoma Multiforme Treatment Market with the largest revenue share in 2023. The predominance of the GBM market can be attributed to various reasons, one being a growing awareness of targeted therapies and immunotherapies. The National Cancer Institute (NCI) has been heavily investing in this type of research, with a host of clinical trials looking at newer classes of drugs for treating GBM. The sub-optimal effects of conventional cytotoxic drugs such as temozolomide underlie the impetus for new classes of drugs. With standard treatment, GBM patients have a median survival of just 12-18 months, according to the National Brain Tumor Society, demonstrating the need for more effective therapies. This has resulted in greater investment in alternative drug classes, including targeted molecular therapy (TMT), immunotherapy (IT), and tumor-treating fields (TTF).

Also, the introduction of new classes of drugs such as bevacizumab (Avastin) in 2009 for recurrent GBM marked the growth of this segment and was approved by the FDA. Moreover, the National Institutes of Health (NIH) stated that it funded more than $200 million in brain cancer research in 2022, with a considerable amount of funding allocated for novel drug classes to treat glioblastoma (GBM) alone.

By Treatment

In 2023, the radiation therapy segment captured a revenue share of 36% in the Glioblastoma Multiforme treatment market. The reason why radiation therapy covers a major share of the market is that it plays an important role in the standard protocol being used to treat GBM. Guidelines from the National Comprehensive Cancer Network (NCCN) state that radiation therapy forms the foundation of GBM treatment, usually in conjunction with surgery and chemotherapy. The effectiveness of radiation therapy in improving survival outcomes for GBM patients has been well-documented. Operative radiation therapy has been shown to increase median survival from 4-5 months to 9-12 months with postoperative radiation therapy, according to the National Cancer Institute. Additionally, new methods to deliver radiation, like IMRT and stereotactic radiosurgery, enable more precise targeting and treatment with less harm to surrounding healthy tissue.

Additionally, the support from the government for radiation therapy research and infrastructures has caused the radiation therapy market to dominate. The National Institutes of Health (NIH) has consistently funded studies exploring innovative radiation approaches for GBM treatment. For example, there are the $30 million the NIH spent on radiation therapy research for brain cancer alone, as shown in the graph for the fiscal year 2022.

By End Use

In 2023, the market for Glioblastoma Multiforme Treatment was dominated by the hospital segment, which accounted for the largest revenue share. This is due to various reasons, the most predominant being that GBM treatment is very complex and requires a multidisciplinary approach and the right medical facilities. Also, hospitals are typically more equipped to give comprehensive care, including surgery, radiation therapy, and systemic treatments, all of which are necessary for GBM management. The American Hospital Association reported 6,093 hospitals in the United States as of 2021, many of them with specialized neuro-oncology units. Due to their advanced diagnostic and therapeutic capabilities, these facilities are often leading treatment centers for GBM patients. For instance, the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program has reported that about 70% of individuals with GBM are treated primarily in the hospital setting.

Furthermore, hospitals are more likely to participate in clinical trials and research programs, which are crucial for advancing GBM treatment. ClinicalTrials.gov, the largest registry of clinical trials worldwide, is maintained by the National Institutes of Health. As per the gov database, 500 plus active clinical trials are listed for GBM treatment by 2022, out of which the majority were hospital based. Being a part of current research enables hospitals to provide the newest available treatment options for GBM patients. Also, the large share of the market can be attributed to the cost-effective reimbursement policies involved in treating patients of GBM. According to the Centers for Medicare & Medicaid Services (CMS), brain cancer treatments (including GBM treatments) comprised a large percentage of Medicare spending on cancer care in hospitals.

Regional Analysis

North America led the Glioblastoma Multiforme Treatment Market in 2023, contributing around 40% of the total market share. Factors contributing to this leadership position include advanced healthcare infrastructure, high healthcare expenditure, and a good research ecosystem. There are more than 12,000 new cases of GBM diagnosed each year in the United States alone, according to the National Cancer Institute, which fuels the need for effective new treatments. In 2023, Europe accounted for a significant market share, and Germany captured the largest regional market. Various key factors, such as supportive government initiatives and support for oncology and GBM studies by the German Federal Ministry of Education and Research (BMBF), are the major factors attributing to the strong market position of this region.

The Asia Pacific is projected to register the highest CAGR during the forecast period. Such rapid growth is driven by a better healthcare infrastructure, growing awareness regarding GBM, and large-scale investments in cancer research and treatment by governments across the globe. The Japanese government, for example, allocated ¥26 billion to cancer genomics research in its budget for 2022, which will likely enhance GBM research and treatment development.

Do You Need any Customization Research on  Glioblastoma Multiforme Treatment Market - Enquire Now

Key Players

Key Service Providers/Manufacturers

• F. Hoffmann-La Roche (Genentech USA): (Avastin, Tecentriq)

• Merck & Co.: (Keytruda, Temodar)

• Pfizer: (Glasdegib, Sutent)

• Amgen: (Depatuxizumab mafodotin, AMG 596)

• Novocure GmbH: (Optune, NovoTTF-200A)

• Eisai Co.: (Gliadel Wafer, Lenvima)

• Teva Pharmaceutical Industries: (Trisenox, Treanda)

• Sun Pharmaceutical Industries: (Odomzo, Yonsa)

• Karyopharm Therapeutics: (Xpovio, Selinexor)

• Denovo Biopharma: (DB102, DB107)

• Curtana Pharmaceuticals: (CT-179, CT-050)

• Amneal Pharmaceuticals: (Carboplatin Injection, Cisplatin Injection)

• Sumitomo Dainippon Pharma: (Brovana, Latuda)

• Daiichi Sankyo Company: (Delytact, Teserpaturev)

• Epitopoietic Research Corporation: (Gliovac, ERC1671)

• Medivir: (Remetinostat, MIV-818)

• Genmab: (Epcoritamab, Tisotumab vedotin)

• AbbVie: (Depatuxizumab mafodotin, Venetoclax)

• Alpha Tau Medical Ltd: (Alpha DaRT, Alpha Beam)

• Moleculin Biotech, Inc.: (WP1122, Annamycin)

Recent Developments

• In June 2024, Merck & Co reported positive results of a phase III clinical trial of a new immunotherapy combination for newly diagnosed GBM patients, with improved progression-free survival.

• In January 2025, the National Cancer Institute initiated a nationwide precision medicine program for GBM, intended to obtain genomic data from 10,000 patients to inform individualized treatment strategies